These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31628854)

  • 1. Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Clin Pharmacol Ther; 2020 Apr; 107(4):1014-1022. PubMed ID: 31628854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
    Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
    Goadsby PJ; Tepper SJ; Watkins PB; Ayele G; Miceli R; Butler M; Severt L; Finnegan M; Szegedi A; Trugman JM; Jakate A
    Cephalalgia; 2019 Dec; 39(14):1753-1761. PubMed ID: 31537107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Ailani J; Lipton RB; Hutchinson S; Knievel K; Lu K; Butler M; Yu SY; Finnegan M; Severt L; Trugman JM
    Headache; 2020 Jan; 60(1):141-152. PubMed ID: 31913519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Dodick DW; Lipton RB; Ailani J; Halker Singh RB; Shewale AR; Zhao S; Trugman JM; Yu SY; Viswanathan HN
    Headache; 2020 Apr; 60(4):686-700. PubMed ID: 32073660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
    Stier B; Fossler M; Liu F; Caltabiano S
    Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
    Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A
    Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.
    Ankrom W; Bondiskey P; Li CC; Palcza J; Liu W; Dockendorf MF; Matthews C; Panebianco D; Reynders T; Wagner JA; Jakate A; Mesens S; Kraft WK; Marcantonio EE
    Clin Transl Sci; 2020 May; 13(3):462-472. PubMed ID: 31899602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults.
    Boinpally R; Trugman J
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):688-695. PubMed ID: 38261231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
    Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
    JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.
    Yang Y; Chen M; Sun Y; Gao B; Chen Z; Wang Z
    CNS Drugs; 2020 May; 34(5):463-471. PubMed ID: 32193827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
    Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.
    Mendell J; Kobayashi F; Shimizu T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):709-718. PubMed ID: 32255542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
    Das S; Armstrong J; Mathews D; Li J; Edeki T
    J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.